Get the Stockscreener App
7.25
0.68%
-0.05
After Hours:
7.22
-0.03
-0.41%
Q 32 Bio Inc stock is traded at $7.25, with a volume of 244.20K.
It is down -0.68% in the last 24 hours and up +53.28% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
See More
Previous Close:
$7.30
Open:
$7.28
24h Volume:
244.20K
Relative Volume:
1.21
Market Cap:
$106.06M
Revenue:
$53.74M
Net Income/Loss:
$29.82M
P/E Ratio:
3.1541
EPS:
2.2986
Net Cash Flow:
$-33.54M
1W Performance:
+24.78%
1M Performance:
+53.28%
6M Performance:
+285.64%
1Y Performance:
+248.56%
1-Day Range:
$6.85
$7.525
1-Week Range:
$5.51
$7.525
52-Week Range:
$1.345
$7.80
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
7.25 | 106.80M | 53.74M | 29.82M | -33.54M | 2.2986 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | H.C. Wainwright | Buy |
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
If You Invested $1,000 in Q32 BIO INC (QTTB) - Stock Titan
Q32 Bio (QTTB) CSO granted 37,500 RSUs and updates holdings - Stock Titan
Q32 Bio (QTTB) awards 53,250 RSUs to its CFO and President - Stock Titan
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Best Momentum Stocks to Buy for March 19th - The Globe and Mail
Q32 Bio (NASDAQ:QTTB) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Best Momentum Stocks to Buy for March 13th - The Globe and Mail
Q32 Bio Hits New HighRegrowth Signals? - RTTNews
Q32 Bio, Inc. Experiences Comprehensive Evaluation Adjustment Amid Financial Landscape Changes - Markets Mojo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), Q32 Bio (QTTB) and Shoulder Innovations, Inc. (SI) - The Globe and Mail
FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat
What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings? - Defense World
Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing - The Globe and Mail
Q1 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat
H.C. Wainwright Maintains Buy on QTTB Q32 Bio Inc. March 2026 - Meyka
H.C. Wainwright reiterates Q32 Bio stock rating with $13 target - Investing.com India
Q32 Bio Reports Q4 2025 Financial Results, Highlights SIGNAL-AA Trial Progress and Strong Financial Runway into 2027 - Minichart
Q32 Bio Inc. (QTTB) Reports Q4 Earnings - AlphaStreet
Q32 Bio Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q32 Bio Inc. 2025 Annual Report: Business Overview, Pipeline, Risks, and Intellectual Property Strategies - Minichart
Q32 Bio 2025 Financial Results: Q4 Net Income $57.7M, Revenue $53.7MNews and Statistics - IndexBox
Q32 Bio (NASDAQ:QTTB) Releases Quarterly Earnings Results, Beats Expectations By $4.71 EPS - MarketBeat
Q32 Bio Inc. releases fourth quarter 2025 results and issues corporate update - Traders Union
Q32 Bio 10-K: $53.7M collaboration revenue drives $29.8M net income - TradingView
Q32 Bio: Q4 Earnings Snapshot - kare11.com
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Q32 Bio: Q4 Financial Overview - Bitget
Q32 Bio Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - Stocktwits
Q32 Bio (QTTB) Projected to Post Earnings on Tuesday - MarketBeat
QTTB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab - MarketBeat
QTTB PE Ratio & Valuation, Is QTTB Overvalued - Intellectia AI
FY2025 Earnings Estimate for Q32 Bio Issued By HC Wainwright - Defense World
Insider Selling: Q32 Bio (NASDAQ:QTTB) CFO Sells 3,995 Shares of Stock - MarketBeat
Insider Selling: Q32 Bio (NASDAQ:QTTB) Insider Sells 2,815 Shares of Stock - MarketBeat
Q32 Bio (QTTB) CSO auto-sells 2,815 shares to cover tax bill - Stock Titan
FY2025 Earnings Forecast for Q32 Bio Issued By HC Wainwright - MarketBeat
Insider Selling: Q32 Bio (NASDAQ:QTTB) CEO Sells $44,630.96 in Stock - MarketBeat
FY2029 Earnings Forecast for Q32 Bio Issued By HC Wainwright - Defense World
Analysts Offer Predictions for Q32 Bio FY2029 Earnings - MarketBeat
Q32 Bio (QTTB) Price Target Increased by 32.35% to 15.30 - Nasdaq
HC Wainwright & Co. Initiates Coverage of Q32 Bio (QTTB) with Buy Recommendation - Nasdaq
H.C. Wainwright initiates Q32 Bio stock coverage with buy rating - Investing.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Q32 Bio (NASDAQ:QTTB) Now Covered by Analysts at HC Wainwright - MarketBeat
QTTBQ32 BIO INC Latest Stock News & Market Updates - Stock Titan
Q32 Bio Inc. $QTTB Shares Sold by Monaco Asset Management SAM - MarketBeat
Opaleye Group reports 1.256M shares in Q32 Bio (NASDAQ: QTTB) - Stock Titan
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight (2026-02-19) - Seeking Alpha
Q 32 Bio Inc Stock (QTTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):